NCT03381716

Brief Summary

The study evaluated the prevalence, presentation, management, and prognosis of coronary heart disease differ according to sex.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
884

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2002

Longer than P75 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 19, 2002

Completed
14 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 29, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 29, 2016

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

December 11, 2017

Completed
11 days until next milestone

First Posted

Study publicly available on registry

December 22, 2017

Completed
Last Updated

December 22, 2017

Status Verified

December 1, 2017

Enrollment Period

14 years

First QC Date

December 11, 2017

Last Update Submit

December 18, 2017

Conditions

Keywords

aortic dissectionsextreatment

Outcome Measures

Primary Outcomes (1)

  • The outcome measure describes aortic disease-related death,aortic dissection, paraplegia, myocardial ischemia, renal insufficiency and other aortic complications.

    The study's primary endpoint during the follow up was the composite of aortic disease-related death, aortic dissection, paraplegia, myocardial ischemia, renal insufficiency and other aortic complications during follow-up.

    2.9years

Study Arms (2)

male

Drug:Beta-blocker,Angiotensin II receptor blocker,Angiotensin-converting enzyme,Calcium-channel blocker,Aspirin,Statin

Drug: drugProcedure: Surgery

female

Drug:Beta-blocker,Angiotensin II receptor blocker,Angiotensin-converting enzyme,Calcium-channel blocker,Aspirin,Statin

Drug: drugProcedure: Surgery

Interventions

drugDRUG

Application bracket

Also known as: thoracic endovascular aortic repair
femalemale
SurgeryPROCEDURE

Surgery

femalemale

Eligibility Criteria

Age21 Years - 89 Years
Sexall(Gender-based eligibility)
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Chinese

You may qualify if:

  • acute aortic dissection

You may not qualify if:

  • Chronic aortic dissection

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Bossone E, LaBounty TM, Eagle KA. Acute aortic syndromes: diagnosis and management, an update. Eur Heart J. 2018 Mar 1;39(9):739-749d. doi: 10.1093/eurheartj/ehx319.

Biospecimen

Retention: SAMPLES WITHOUT DNA

patients

MeSH Terms

Conditions

Aortic DissectionCoitus

Interventions

Pharmaceutical PreparationsEndovascular Aneurysm RepairSurgical Procedures, Operative

Condition Hierarchy (Ancestors)

Dissection, Blood VesselAneurysmVascular DiseasesCardiovascular DiseasesAcute Aortic SyndromeAortic DiseasesSexual BehaviorBehavior

Intervention Hierarchy (Ancestors)

Endovascular ProceduresVascular Surgical ProceduresCardiovascular Surgical ProceduresBlood Vessel Prosthesis ImplantationVascular GraftingMinimally Invasive Surgical ProceduresProsthesis Implantation

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Correlation between sex and prognosis of acute aortic dissection in the Chinese population

Study Record Dates

First Submitted

December 11, 2017

First Posted

December 22, 2017

Study Start

June 19, 2002

Primary Completion

May 29, 2016

Study Completion

May 29, 2016

Last Updated

December 22, 2017

Record last verified: 2017-12

Data Sharing

IPD Sharing
Will not share